NEW YORK (Reuters) - Life sciences company Bayer AG (BAYGn.DE) said on Friday it would discontinue the sale of its birth control product Essure in the United States, citing a decline in sales of the ...

Essure is a permanent birth control device that consists of two small metal coils inserted through the vagina into the fallopian tubes (see image, below). The device is popular among women and ...

Bayer will discontinue the marketing and sales of the sterilization device Essure in all countries outside of the United States, the company announced on Monday. While a number of reports have linked ...

WASHINGTON (MEDIA GENERAL) – After suffering symptoms of extreme pelvic pain, bleeding and migraines, former users of a birth control device known as Essure are pushing for Congress to immediately ...

A permanent birth-control implant called Essure will need to be labeled with a stronger warning that lists potentially serious risks of the device, the Food and Drug Administration announced this week ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. WASHINGTON — The maker of a permanent ...

The FDA announced Monday that it will add its strictest warning to the label of Essure, a sterilization device in the form of flexible metal coils inserted into the fallopian tubes. But the decision ...

After receiving thousands of complaints about the adverse effects of the birth control implant Essure, the FDA announced late Wednesday that it has updated the list of risks and complications ...

Even though it’s no longer on the market, new data has emerged around potential side effects of the permanent birth control device Essure. The device, pulled from the US market two years ago amid ...

Federal health regulators plan to warn consumers more strongly about Essure, a contraceptive implant that has drawn thousands of complaints from women reporting chronic pain, bleeding and other health ...

Five months after convening an advisory committee meeting to discuss concerns about the safety of Essure, the only non-surgical permanent contraceptive, the Food and Drug Administration on Monday ...

MOUNTAIN VIEW, Calif., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS),developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, ...